ReviewCancer journal (Sudbury, Mass.)
Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Review
- Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling.Genome research · 2025Article
- Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.Current pharmaceutical design · 2025Review
- Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer.Cell reports. Medicine · 2023Review
- Review
- Systemic Investigation Identifying Salivary miR-196b as a Promising Biomarker for Early Detection of Head-Neck Cancer and Oral Precancer Lesions.Diagnostics (Basel, Switzerland) · 2021Article
- The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer.International journal of clinical oncology · 2021Review
- Triple-negative breast cancer: A run-through of features, classification and current therapies.Oncology letters · 2021Review
- Triple-negative breast cancer: promising prognostic biomarkers currently in development.Expert review of anticancer therapy · 2021Review
- Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?American journal of blood research · 2020Review
- The emerging role of cell-free DNA as a molecular marker for cancer management.Biomolecular detection and quantification · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A primary goal of personalized medicine is to develop tumor-specific biomarkers to aid in treatment selection and to better evaluate response to targeted therapies. The assessment of circulating blood markers as surrogate real-time biopsies of disease status, termed liquid biopsies, has been under investigation. There are many different types of liquid biopsies each with different functionalities and limitations. These include tumor markers, circulating tumor cells, cell-free DNA, and extracellular vesicles including exosomes. Multiple clinical trials have evaluated liquid biopsies as prognostic biomarkers with positive results. Additional studies are underway to evaluate liquid biopsies as predictive biomarkers, pharmacodynamic biomarkers, and surrogate efficacy endpoints for treatment response evaluation. There are several challenges in and barriers to implementation of liquid biopsies into clinical trials and subsequently into routine clinical practice, which are addressed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.